EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MATN1‐AS1 Promotes Tumour Metastasis and Sunitinib Resistance via E2F2 in Clear Cell Renal Cell Carcinoma

Haibing Xiao iD, Mintian Fei, Qili Xu, Yu Gao, Rui Feng, Chaozhao Liang iD, Baojun Wang, Haolin Li

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Haibing Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Drug Resistance, Neoplasm, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Key Project of Natural Science Research project of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It has become increasingly recognised that MATN1‐AS1 is involved in multiple tumour development. The role of MATN1‐AS1 in clear cell renal cell carcinoma (ccRCC), however, is still largely unrecognised. This study investigated the molecular functions of MATN1‐AS1 in promoting ccRCC metastasis and sunitinib resistance. MATN1‐AS1 was found to be mainly located in the cytoplasm and was upregulated in ccRCC, and a positive association was seen between greater levels of MATN1‐AS1 expression and worse clinical outcomes. Downregulating MATN1‐AS1 significantly hindered cell proliferation, migration, invasion and epithelial‐mesenchymal transition (EMT). MATN1‐AS1 promoted tumour growth and metastasis in vivo. Mechanismly, MATN1‐AS1 targeted microRNA miR‐214‐5p, thereby upregulating E2F2 and promoting E2F2‐mediated EMT. We discovered that MATN1‐AS1 also promoted sunitinib resistance via E2F2 in vitro. Collectively, our research uncovered the protumor characteristics of MATN1‐AS1 and suggested it as a therapeutic target for reverse sunitinib resistance in ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellSunitinibDrug Resistance, NeoplasmKidney NeoplasmsE2F2 Transcription FactorRNA, Long NoncodingHumansEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticCell Line, TumorAnimalsCell MovementCell ProliferationMiceNeoplasm MetastasisMaleFemaleMicroRNAsMice, Nude

Stichwörter der Autor:innen

E2F2EMTMATN1‐AS1ccRCClncRNAsunitinib resistance

Substanzen

SunitinibE2F2 Transcription FactorRNA, Long NoncodingE2F2 protein, humanMicroRNAs

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Anhui Provincal Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui, China.
  • Department of Urology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

ORCID-Profile: Haibing Xiao, Chaozhao Liang

Förderung

  • the Key Project of Natural Science Research project of Anhui Province

Zitieren

APA

Xiao, H., Fei, M., Xu, Q., Gao, Y., Feng, R., Liang, C., Wang, B., & Li, H. (2025). MATN1‐AS1 Promotes Tumour Metastasis and Sunitinib Resistance via E2F2 in Clear Cell Renal Cell Carcinoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70428

Vancouver

Xiao H, Fei M, Xu Q, Gao Y, Feng R, Liang C, et al. MATN1‐AS1 Promotes Tumour Metastasis and Sunitinib Resistance via E2F2 in Clear Cell Renal Cell Carcinoma. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70428

BibTeX
@article{Xiao2025,
  author = {Xiao, Haibing and Fei, Mintian and Xu, Qili and Gao, Yu and Feng, Rui and Liang, Chaozhao and Wang, Baojun and Li, Haolin},
  title = {MATN1‐AS1 Promotes Tumour Metastasis and Sunitinib Resistance via E2F2 in Clear Cell Renal Cell Carcinoma},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70428}
}
Kostenlos starten →